Patents by Inventor André Warnecke

André Warnecke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE
    Publication number: 20230023537
    Abstract: The present invention provides a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, for the controlled delivery and release of Agent.
    Type: Application
    Filed: June 3, 2022
    Publication date: January 26, 2023
    Inventors: Felix Kratz, Khalid Abu Ajaj, André Warnecke, Stephan David Koester, Friederike I. Nollmann, Simon Waltzer, Olga Fuchs, Javier García Fernandez
  • Delivery systems for controlled drug release
    Patent number: 11384104
    Abstract: The present invention provides a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, for the controlled delivery and release of Agent.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: July 12, 2022
    Assignee: CENTURION BIOPHARMA CORPORATION
    Inventors: Felix Kratz, Khalid Abu Ajaj, André Warnecke, Stephan David Koester, Friederike I. Nollmann, Simon Waltzer, Olga Fuchs, Javier García Fernandez
  • DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE
    Publication number: 20190002484
    Abstract: The present invention provides a compound having the structure of Formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or isomer thereof, for the controlled delivery and release of Agent.
    Type: Application
    Filed: June 17, 2016
    Publication date: January 3, 2019
    Inventors: Felix Kratz, Khalid Abu Ajaj, André Warnecke, Stephan David Koester, Friederike I. Nollmann, Simon Waltzer, Olga Fuchs, Javier García Fernandez
  • Combinations Of Albumin-Based Drug Delivery Systems
    Publication number: 20180028679
    Abstract: The present invention relates to a composition comprising at least two different albumin-based drug delivery systems, as well as to a pharmaceutical composition comprising said composition.
    Type: Application
    Filed: September 25, 2017
    Publication date: February 1, 2018
    Inventors: Felix Kratz, Andre Warnecke
  • Combinations of albumin-based drug delivery systems
    Patent number: 9801949
    Abstract: The present invention relates to a composition comprising at least two different albumin-based drug delivery systems, as well as to a pharmaceutical composition comprising said composition.
    Type: Grant
    Filed: February 21, 2013
    Date of Patent: October 31, 2017
    Assignee: KTB TUMORFORSCHUNGSGESELLSCHAFT MBH
    Inventors: Felix Kratz, Andre Warnecke
  • COMBINATIONS OF ALBUMIN-BASED DRUG DELIVERY SYSTEMS
    Publication number: 20150023912
    Abstract: The present invention relates to a composition comprising at least two different albumin-based drug delivery systems, as well as to a pharmaceutical composition comprising said composition.
    Type: Application
    Filed: February 21, 2013
    Publication date: January 22, 2015
    Inventors: Felix Kratz, Andre Warnecke
  • Prodrugs
    Patent number: 8642555
    Abstract: The present invention relates to a prodrug comprising at least one cytostatic agent, wherein said prodrug is cleavable by prostate-specific antigen (PSA), a process for preparing said prodrug and a pharmaceutical composition containing said prodrug in a pharmaceutically effective amount, for use in the treatment of cancer.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: February 4, 2014
    Assignee: KTB Tumorforschungsgesellschaft mbH
    Inventors: Felix Kratz, Andre Warnecke, Bakheet Elsadek
  • Acid-labile trigger units
    Patent number: 8609860
    Abstract: The present invention relates to a compound comprising an imine bond as an acid-labile trigger group, the use of such an imine bond as an acid-labile trigger group, a process of cleaving the imine bond in said compound, and a pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: June 21, 2010
    Date of Patent: December 17, 2013
    Assignee: KTB Tumorforschungsgesellschaft mbH
    Inventors: André Warnecke, Ivonne Müller
  • Linear self-eliminating oligomers
    Patent number: 8597631
    Abstract: The present invention relates to a linear self-eliminating oligomer comprising one or more cleavable triggers, linker units, effector units and a carrier, and a pharmaceutical composition comprising said oligomer.
    Type: Grant
    Filed: April 30, 2009
    Date of Patent: December 3, 2013
    Assignee: KTB Tumorforschungsgesellschaft mbH
    Inventor: André Warnecke
  • LINEAR SELF-ELIMINATING OLIGOMERS
    Publication number: 20120270937
    Abstract: The present invention relates to a linear self-eliminating oligomer comprising one or more cleavable triggers, linker units, effector units and a carrier, and a pharmaceutical composition comprising said oligomer.
    Type: Application
    Filed: April 30, 2009
    Publication date: October 25, 2012
    Inventor: André Warnecke
  • ACID-LABILE TRIGGER UNITS
    Publication number: 20120142711
    Abstract: The present invention relates to a compound comprising an imine bond as an acid-labile trigger group, the use of such an imine bond as an acid-labile trigger group, a process of cleaving the imine bond in said compound, and a pharmaceutical composition comprising said compound.
    Type: Application
    Filed: June 21, 2010
    Publication date: June 7, 2012
    Applicant: KTB TUMORFORSCHUNGSGESELLSCHAFT MBH
    Inventors: André Warnecke, Ivonne Müller
  • PRODRUGS
    Publication number: 20120094892
    Abstract: The present invention relates to a prodrug comprising at least one cytostatic agent, wherein said prodrug is cleavable by prostate-specific antigen (PSA), a process for preparing said prodrug and a pharmaceutical composition containing said prodrug in a pharmaceutically effective amount, for use in the treatment of cancer.
    Type: Application
    Filed: March 9, 2010
    Publication date: April 19, 2012
    Applicant: KTB TUMORFORSCHUNGSGESELLSCHAFT MBH
    Inventors: Felix Kratz, Andre Warnecke, Bakheet Elsadek
  • PROTEIN-BINDING METHOTREXATE DERIVATIVES, AND MEDICAMENTS CONTAINING THE SAME
    Publication number: 20100041615
    Abstract: The invention relates to methotrexate derivatives which contain a protein-binding group and can be enzymatically cleaved in the body such that the active substance or a low-molecular active substance derivative is released. Also disclosed is a method for producing methotrexate derivatives, the use thereof, and medicaments comprising methotrexate derivative.
    Type: Application
    Filed: July 25, 2007
    Publication date: February 18, 2010
    Inventors: Felix Kratz, Andre Warnecke
  • Protein-bound derivatives of platinum complexes containing cyclobutane1, 1-dicarboxyllate ligands
    Patent number: 7141691
    Abstract: The invention concerns low-molecular platinum complexes containing cyclobutane-1,1-dicarboxylate ligands that contain a protein-binding group.
    Type: Grant
    Filed: March 18, 2004
    Date of Patent: November 28, 2006
    Assignee: KTB Tumorforschungs GmbH
    Inventors: Felix Kratz, André Warnecke
  • Protein-bound derivatives of platinum complexes containing cyclobutane1,1-dicarboxyllate ligands
    Publication number: 20060089341
    Abstract: The invention concerns low-molecular platinum complexes containing cyclobutane-1,1-dicarboxylate ligands that contain a protein-binding group.
    Type: Application
    Filed: March 18, 2004
    Publication date: April 27, 2006
    Inventors: Felix Kratz, Andre Warnecke